Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers: Does Human Papillomavirus Make a Difference?

Clin Oncol (R Coll Radiol). 2015 Dec;27(12):751-3. doi: 10.1016/j.clon.2015.09.003. Epub 2015 Sep 26.

Authors

S Kane¹, V M Patil², A Joshi², V Noronha², V Muddu², S Dhumal², S Juvekar³, S Arya³, A D'Cruz⁴, A Bhattacharjee⁵, K Prabhash²

Affiliations

¹ Department of Pathology, Tata Memorial Hospital, Mumbai, India.
² Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
³ Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, India.
⁴ Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India.
⁵ Division of Clinical Research and Biostatistics, Tata Memorial Hospital, Mumbai, India; Malabar Cancer Centre, Kerala, India.

PMID: 26412438
DOI: 10.1016/j.clon.2015.09.003

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carboplatin / administration & dosage
Chemotherapy, Adjuvant
Cisplatin / administration & dosage
Cohort Studies
Docetaxel
Female
Follow-Up Studies
Humans
Male
Middle Aged
Mouth Neoplasms / drug therapy*
Mouth Neoplasms / pathology
Mouth Neoplasms / virology
Neoadjuvant Therapy*
Neoplasm Staging
Paclitaxel / administration & dosage
Papillomaviridae / pathogenicity*
Papillomavirus Infections / complications
Papillomavirus Infections / drug therapy*
Papillomavirus Infections / virology
Prognosis
Survival Rate
Taxoids / administration & dosage
Young Adult

Substances

Taxoids
Docetaxel
Carboplatin
Paclitaxel
Cisplatin